The clinical outcomes of the GEMINI 1 and GEMINI 2 studies are discussed in this touchOPHTHALMOLOGY interview with Prof. Christopher Lievens (Southern College of Optometry, Memphis, Tennessee, USA). If approved, AGN-190584 is expected to be the first eye drop for the treatment of presbyopia, the eye’s reduced ability to focus on near objects.
The presentation entitled ‘Extended Depth of Focus from AGN-190584 in GEMINI 1 and GEMINI 2 Pooled Phase 3 Studies’ was presented at the The Association for Research in Vision and Ophthalmology, May 01-04, 2022
- What is AGN-190584 and what is the rationale for its use in the treatment of presbyopia?
- What have the GEMINI studies taught us about the efficacy and safety of AGN-190584 in this indication?
- What were the aims and design of the current analysis?
- What were the study findings and what have they taught us about the action of AGN-190584?
- What questions remain unanswered and what future studies are planned?
Disclosures: Christopher Lievens is a consultant for and received grant/research support from Allergan.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the virtual ARVO 2022.
Share this Video
Related Videos In Anterior Segment
John D Sheppard, Hawaiian Eye and Retina 2023: Phaco and keratopathy – sequential or combined keratoplasty?
It was a pleasure to have the opportunity to meet with Dr John D Sheppard (Eastern Virginia Medical School, Norfolk, VA, USA) about his presentation on what to consider when choosing between sequential or combined keratoplasty. Questions: What are the advantages and disadvantages of combined phacoemulsification and keratoplasty versus sequential surgery? (0:10) What patient factors […]
John D Sheppard, Hawaiian Eye and Retina 2023: Highlights
We were delighted to speak with Dr John D Sheppard (Eastern Virginia Medical School, Norfolk, VA, USA) about his highlights from Hawaiian Eye and Retina 2023, and his views on the role of penetrating keratoplasty in the era of selective lamellar keratoplasty. Questions: What have you gained most from attending the Hawaiian Eye meeting? (0:09) […]
Chhavi Saini, ASCRS 2022: Clinical outcomes of Boston keratoprosthesis type 2
The Boston Keratoprosthesis type II (BK2) device may be the only viable option to salvage vision in patients with severe cicatrizing ocular surface disease. The prior BK2 model was modified to the present day (click-on) model in 2009. The clinical outcomes of the current click-on BK2 model is discussed in this touchOPHTHALMOLOGY interview with Dr […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!